San Diego Convention Center,
San Diego, CA, USA
Manufacturing Strategy, AI & Bioprocessing 4.0 Track
The biomanufacturing landscape is evolving fast. With new modalities, global supply-chain volatility, and digital transformation reshaping production, success depends on strategy as much as technology. The Manufacturing Strategy track unites leaders in process innovation, AI, facility design, and operations to discuss how to future-proof manufacturing for flexibility, speed, and quality.
Building the Future of Biomanufacturing that’s Digital, Agile, and Global - Take a Look at Key Topics:
Digital Twins, AI & Real-Time Process Control
Manufacturing is being transformed by the adoption of digital twins, AI/ML models and real-time monitoring to improve predictability, reduce variability and speed up scale-up or tech-transfer. Join sessions like “Machine-Learning-Enhanced Digital Twins for Quality Prediction” to see how companies are leveraging virtual replicas and analytics to simulate scenarios, de-risk operations and accelerate decision-making.
Smart, Flexible & Agile Manufacturing Models
With increasing modality diversity, regional launch requirements and shorter timelines, manufacturing strategy must shift to flexible, agile, modular models. Talks such as “Smart Factories of the Future: Automation, Robotics, and Data Architecture” will reflect moves towards smaller footprints, multiproduct capabilities and rapid pivoting of manufacturing lines.
Supply Chain Resilience & Strategic Tech Transfer
Manufacturing strategy is no longer just about the plant - it’s about the entire value chain: tech transfer, raw-material security, global site readiness and scalability. Sessions like “Achieving Supply Chain Resilience in Bioprocessing” will underline how companies are embedding manufacturing strategy early and building resilient networks amid global volatility.
Decision-Making Frameworks for Process Strategy: Continuous vs. Fed-Batch
As bioprocess intensification and new modalities emerge, a key strategic question remains: which process model delivers the optimal balance of cost, speed, risk and flexibility? Companies must evaluate molecule type, facility readiness, supply-chain implications and digital capabilities when selecting their manufacturing strategy. Join the panel session: “Continuous vs. Fed-Batch Upstream – The Ongoing Debate” to see why this remains a critical issue.
